Table 1.
Main characteristics of included studies assessing QoL after CRS with HIPEC
| Author/year | Country | Study period | Study design | Patients (n) | Control group | Primary tumor origin | QoL instrument (s) | Time points of assessment |
|---|---|---|---|---|---|---|---|---|
| Albertsmeier27 | Germany | NR | P | 40 | No | CRC 18%, gastric 15%, PMP 13%, ovarian 13%, meso 3% | EORTC QLQ-C30 | Baseline and 3, 9, and 18 months after surgery |
| Bayat39 | Canada | 2011 to 2017 | P | 158 | No | Low-grade appendix 45%, CRC, high-grade appendix, small bowel 44%, peritoneal mesothelioma 11% | EORTC QLQ-C30, EORTC QLQ-CR29 | 3, 6, and 12 months |
| Chia22 | Singapore | 2012 to 2015 | P | 23 | No | CRC 100% | EORTC QLQ-C30, EORTC QLQ-CR29 | Baseline and 3, 6, and 12 months after surgery |
| Dodson28 | USA | 2000 to 2015 | P | 598 | No | CRC 22%, ovarian 3.7%, meso 8.4%, appendix 58%, small bowel 2%, others 6.2% | SF-36, FACT-C, BPI, CES-D, ECOG | Baseline and 3, 6, 12, and 24 months after surgery |
| Hamilton29 | Canada | 2011 to 2014 | R | 42 | Yes | CRC 38%, meso 4.8%, appendix 55%, small bowel 2% | EORTC QLQ-C30 | 6 months after surgery |
| Hill30 | USA | 2001 to 2009 | P | 61 | No | CRC 100% | SF-36, FACT-C, BPI, CES-D, ECOG | Baseline and 3, 6, and 12 months after surgery |
| Hinkle31 | USA | NR | R | 36 | Yes | CRC 14%, ovarian 22%, meso 3%, appendix 39%, small bowel 3%, desmoplastic small round cell tumor 11%, primary peritoneal 6%, fibrolamellar hepatocellular carcinoma 3% | FACT-C | Baseline and 2 weeks, 1, 3, 6, and 12 months after surgery |
| Kopanakis32 | Greece | 2011 to 2015 | P | 80 | No | CRC 24%, gastric 6%, PMP 19%, ovarian 35%, meso 9%, endometrial 5%, sarcoma 3% | FACT-C | Baseline and 1, 3, 6, 12, 18 and 24 months after surgery |
| Macrí33 | Italy | 2003 to 2007 | P | 17 | No | CRC 41%, gastric 29%, ovarian 29% | FACT | Baseline and 3 and 6 months after surgery |
| McQuellon35 | USA | 1995 to 1997 | P | 64 | No | CRC 25%, gastric 17%, PMP 2%, ovarian 6%, meso 9%, appendix 23%, small bowel 2%, sarcoma 5%, other gastrointestinal 2%, pancreas 2%, malignant neoplasms 8% | FACT-C, BPI, CES-D, ECOG, ADL subscale items | Baseline and 2 weeks, 3, 6, and 9 months after surgery |
| McQuellon34 | USA | 1998 to 2005 | P | 96 | No | CRC 25%, gastric 4%, ovarian 5%, meso 9%, appendix 38%, miscellaneous 19% | SF-36, FACT-C, BPI, CES-D, ECOG | Baseline and 3, 6, and 12 months after surgery |
| Passot36 | France | 2007 to 2011 | P | 216 | No | CRC 26%, gastric 6%, PMP 19%, meso 8%, ovarian 35%, primary serous peritoneal carcinoma 4%, others 5% | GIQLI | Baseline and 1, 3, 6, and 12 months after surgery |
| Tsilimparis37 | Germany | 2005 to 2010 | P | 90 | No | CRC 21%, gastric 10%, PMP 16%, ovarian 19%, meso 13%, appendix 16%, small bowel 1%, malignant mixed mesodermal tumor 1% | EORTC QLQ-30 | Baseline and 1, 6, 12, 24, and 36 months after surgery |
| Tuttle38 | USA | 2001 to 2005 | P | 35 | No | CRC 20%, gastric 6%, meso 9%, appendix 54%, small bowel 6%, gallbladder 3%, unknown 3% | FACT-C | Baseline and 4, 8, and 12 months after surgery |
ADL subscale items, activities of daily living (10-item activities of daily living subscale is part of SF-36), BPI brief pain inventory, CES-D center of epidemiologic studies depression, CRC colorectal carcinoma, CRS cytoreductive surgery, ECOG Eastern Cooperative Oncology Group Performance status, EORTC QLQ-C30/CR29 European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaires, FACT-(C) Functional Assessment of Cancer Therapy (+ colon subscale), GIQLI Gastro-Intestinal Quality of Life Index, HIPEC hyperthermic intraperitoneal chemotherapy, Meso peritoneal mesothelioma, NR not reported, P prospective study design, PMP pseudomyxoma peritonei, QoL quality of life, R retrospective study design, SF-36 medical outcomes study 36-item short-form health survey